Advancing the Standard of Care
Shattuck Labs (shattucklabs.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 58th percentile of 19251 Healthcare brands.
Shattuck Labs is a clinical-stage biopharmaceutical company headquartered in Austin, focused on developing DR3-targeting antibodies for inflammatory and immune-mediated diseases such as inflammatory bowel disease (IBD) and hidradenitis suppurativa. Its lead program, SL-325, is positioned as the first clinical-stage monoclonal antibody targeting DR3, intended to offer improved inhibition and efficacy compared to existing TL1A-targeting therapies. The company aims to establish DR3 as a foundational therapeutic target and serves patients, healthcare professionals, investors, and biopharmaceutical partners.
| Brand Name | Shattuck Labs |
|---|---|
| Domain | shattucklabs.com |
| Industry | Healthcare |
| Headquarters | Austin |
| Main Competitors | Prometheus Biosciences, Merck & Co. (81/100), Roche (81/100), Sanofi (90/100), Pfizer (89/100), AbbVie (83/100), Takeda (87/100) |
Moz Domain Authority 36/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Shattuck Labs is advancing DR3-targeting antibodies to raise the standard of care in IBD and other inflammatory, immune-mediated diseases." (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Webflow.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Shattuck Labs?", Claude could identify the brand as of October 2026. Shattuck Labs is a clinical-stage biopharmaceutical company developing dual-sided fusion protein therapeutics for cancer and other diseases, using a proprietary platform called ARC (Agonist Redirected Checkpoint) technology that combines checkpoint blockade with immune agonism in Best known for Its ARC bifunctional fusion protein platform that combines checkpoint inhibition with immune agonist activity in one molecule.
When asked "Best brands similar to Shattuck Labs?", Claude would recommend Shattuck Labs as of October 2026. It's a notable player in next-generation immuno-oncology biologics, so it would come up naturally in discussions of innovative checkpoint/agonist combination therapeutics.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Shattuck Labs's main competitors in Healthcare: Merck & Co. (81/100), Roche (81/100), Sanofi (90/100), Pfizer (89/100), AbbVie (83/100).
Sources: Brand Analyzer scan
Shattuck Labs has limited AI-search visibility, scoring 26/100 on Brand Analyzer's AI visibility composite (visibility 19, trust 19, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Shattuck Labs official site
Shattuck Labs is headquartered in Austin. Shattuck Labs operates in the Healthcare category.
Sources: Wikidata
Shattuck Labs scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Shattuck Labs official site
Shattuck Labs' primary offering is SL-325, a clinical-stage monoclonal antibody that targets the DR3 receptor. It is being developed for inflammatory bowel disease (IBD) and other inflammatory, immune-mediated diseases such as hidradenitis suppurativa, with claimed advantages in affinity, epitope specificity, and Fc-silencing over existing TL1A-targeting treatments.
Sources: Shattuck Labs official site
Shattuck Labs is a clinical-stage biopharmaceutical company headquartered in Austin that develops antibody therapies targeting DR3, a receptor implicated in inflammatory and immune-mediated diseases such as inflammatory bowel disease (IBD) and hidradenitis suppurativa.
Sources: Shattuck Labs official site
Shattuck Labs develops DR3-targeting monoclonal antibodies aimed at treating inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is designed to inhibit the DR3 receptor pathway with high affinity, epitope specificity, and Fc-silencing, with the goal of improving remission rates in conditions like IBD compared to existing TL1A-targeting therapies.
Sources: Shattuck Labs official site
Shattuck Labs can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Shattuck Labs official site
Shattuck Labs is known for developing SL-325, described as the first clinical-stage monoclonal antibody targeting DR3, positioning the company as a pioneer in establishing DR3 as a therapeutic target for IBD and other inflammatory diseases.
Sources: Shattuck Labs official site
Shattuck Labs' work is relevant to patients with inflammatory and immune-mediated diseases such as IBD and hidradenitis suppurativa, as well as healthcare professionals who may prescribe or study its therapies, and investors and biopharmaceutical partners interested in its drug development pipeline.
Sources: Shattuck Labs official site
Shattuck Labs scores 26/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Shattuck Labs has a weak AI-visibility profile at 26/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is trust (19/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 36/100 and thin schema.org structured data. In a live check, Claude could already identify Shattuck Labs from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Shattuck Labs: Sevagram (77/100), Sesame Communications (77/100), Shimmer (77/100), Shofu (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.